Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Erik Harris Sells 10,539 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Erik Harris sold 10,539 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $240,289.20. Following the transaction, the executive vice president directly owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. This trade represents a 10.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $22.07 on Wednesday. The stock’s 50 day moving average price is $23.82 and its 200 day moving average price is $29.24. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $42.37. The company has a market cap of $2.13 billion, a PE ratio of -3.78 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same period last year, the business posted ($1.39) EPS. Ultragenyx Pharmaceutical’s revenue was up 25.5% compared to the same quarter last year. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of research reports. TD Cowen reduced their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Guggenheim decreased their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Robert W. Baird lowered their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Leerink Partners cut their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Finally, Bank of America decreased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. Sixteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Management presentation transcript from TD Cowen’s 46th Annual Health Care Conference is available; this is informational for modeling product timelines and pipeline commentary but contains no new regulatory decisions. TD Cowen Presentation Transcript
• Negative Sentiment: Large, concentrated insider selling by multiple senior executives (CEO Emil Kakkis sold 54,404 shares; several EVPs, the CFO and CAO also sold material blocks) — these trades reduced several insiders’ holdings by ~3–10% and totaled well over $1M for the CEO alone. Such coordinated/large insider liquidity can signal personal cash needs or tax planning, but markets often read it as a negative signal for near-term sentiment. SEC filing (CEO sale) here: Insider Sale SEC Filing
• Negative Sentiment: Multiple law firms have announced or are soliciting lead plaintiffs for a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering Aug 3, 2023–Dec 26, 2025; several firms set April 6 lead‑plaintiff deadlines. The proliferation of notices and a filed class action increases legal and financial uncertainty and is likely exerting downward pressure on the stock. Example notice: Kessler Topaz Class Action Notice

Institutional Trading of Ultragenyx Pharmaceutical

A number of hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its holdings in Ultragenyx Pharmaceutical by 1,116,754.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 122,854 shares of the biopharmaceutical company’s stock valued at $2,826,000 after acquiring an additional 122,843 shares during the last quarter. Alberta Investment Management Corp purchased a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $883,000. Mercer Global Advisors Inc. ADV raised its position in shares of Ultragenyx Pharmaceutical by 17.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 2,036 shares during the period. Krensavage Asset Management LLC acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at $3,442,000. Finally, Empowered Funds LLC purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $66,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.